版本:
中国

BRIEF-SillaJen and Transgene enroll first European patient in Phase 3 trial for Pexa-Vec

April 24 SillaJen Inc:

* SillaJen and Transgene announce the enrollment of the first European patient in multinational Phase 3 trial for Pexa-Vec in advanced liver cancer

* Enrollment of the first European patient triggers a $4 million USD milestone to be paid to Sillajen by Transgene Source text for Eikon: Further company coverage:, (Gdynia Newsroom)

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐